Sarepta Therapeutics(GB:0L35)
$14.16-0.47 (-3.25%)
GB:0L35
Sarepta Therapeutics financials statements
$14.16
At close:-0.47 (-3.25%)
Sarepta Therapeutics (0L35) Income Statement
3 Followers
Sarepta Therapeutics Income Statement
Last quarter (Q3 2026), Sarepta Therapeutics's total revenue was $381.35M, a decrease of 4.51% from the same quarter last year. In Q3, Sarepta Therapeutics's net income was $-28.46M. See Sarepta Therapeutics’s key income statements, including revenue, expenses, profit, and income.
| Income Statement | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| $ 2.20B | $ 1.90B | $ 1.24B | $ 933.01M | $ 701.89M | |
| $ 1.32B | $ 1.58B | $ 1.09B | $ 793.02M | $ 604.84M | |
| $ 1.97B | $ 1.36B | $ 1.36B | $ 1.33B | $ 1.06B | |
| Depreciation and Amortization | $ 44.52M | $ 37.72M | $ 44.40M | $ 41.86M | $ 38.02M |
| $ -647.97M | $ 316.89M | $ -453.69M | $ -594.85M | $ -317.41M | |
| $ -657.77M | $ 218.08M | $ -267.82M | $ -536.20M | $ -459.71M | |
| $ -44.45M | $ 42.69M | $ -252.27M | $ -153.76M | $ 40.76M | |
| $ -702.23M | $ 260.77M | $ -520.10M | $ -689.96M | $ -418.95M | |
| $ -713.41M | $ 235.24M | $ -535.98M | $ -703.49M | $ -418.78M | |
| Per Share Metrics | |||||
| Basic EPS | $ -7.13 | $ 2.47 | $ -5.80 | $ -8.03 | $ -5.15 |
| Diluted EPS | $ -7.13 | $ 2.34 | $ -5.80 | $ -8.03 | $ -5.15 |
| Weighted Average Shares Outstanding | 104.79M | 95.08M | 92.40M | 87.56M | 81.26M |
| Weighted Average Shares Outstanding (Diluted) | 104.79M | 107.88M | 92.40M | 87.56M | 81.26M |
Currency in USD

